Tumor suppresser gene p53 expression in premalignant lesions and gastric carcinoma - Prognostic value

被引:1
|
作者
Vukobrat-Bijedic, Zora [1 ]
Radovic, Svjetlana [2 ]
Husic-Selimovic, Azra [1 ]
Gornjakovic, Srdan [1 ]
机构
[1] Univ Sarajevo, Ctr Clin, Gastroenterohepatol Clin, Sarajevo 71000, Bosnia & Herceg
[2] Univ Sarajevo, Fac Med, Inst Pathol, Sarajevo 71000, Bosnia & Herceg
关键词
intestinal metaplasia (IM); epithelial dysplasia; Helicobacter pylori (H. pylori); p53;
D O I
10.17305/bjbms.2007.3080
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of the study was to verify the presence of mutated tumor suppresser gene p53 in intestinal mucosa with histologically confirmed premalignant lesions and gastric carcinoma, and assess its prognostic value. The paper presents prospective study that included So patients with gastric adeno-carcinoma of intestinal type that were treated at Gastroenterohepatology Clinic, and So patients with histologically confirmed chronic atrophic H pylori positive gastritis. In the mucosa biopsy samples, we analyzed presence, frequency and severity of inflammatory-regenerative, metaplastic and dysplastic changes. We typed intestinal metaplasia immunohistochemically and confirmed the presence of p53 onco-protein in antigen positive gastric carcinoma cells, and evaluated its prognostic value. Our results suggest that H, pylori acts as an initiator of inflammatory processes in gastric mucosa, which are followed by emergence of precancerous lesions. p53 is expressed late in carcinogenesis (14%) and as such, may be considered as an indicator of transformation of premalignant into malignant lesion.
引用
收藏
页码:7 / 10
页数:4
相关论文
共 50 条
  • [1] Prognostic value of cyclin E and p53 expression in gastric carcinoma
    Sakaguchi, T
    Watanabe, A
    Sawada, H
    Yamada, Y
    Yamashita, J
    Matsuda, M
    Nakajima, M
    Miwa, T
    Hirao, T
    Nakano, H
    [J]. CANCER, 1998, 82 (07) : 1238 - 1243
  • [2] p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions
    Ajiki, T
    Onoyama, H
    Yamamoto, M
    Asaka, K
    Fujimori, T
    Maeda, S
    Saitoh, Y
    [J]. HEPATO-GASTROENTEROLOGY, 1996, 43 (09) : 521 - 526
  • [3] EXPRESSION OF P53 IN GASTRIC-CANCER - PROGNOSTIC VALUE
    SUNDBLAD, A
    PELLICER, EM
    MEHTA, P
    AHN, C
    BATTIFORA, H
    [J]. MEDICINA-BUENOS AIRES, 1994, 54 (03) : 216 - 220
  • [4] Cumulative prognostic value of p16/CDKN2 and p53 oncoprotein expression in premalignant laryngeal lesions
    Gallo, O
    Santucci, M
    Franchi, A
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (15) : 1161 - 1163
  • [5] Is the p53 gene mutation at prognostic value in hepatocellular carcinoma?
    Ng, IOL
    Fan, ST
    [J]. ARCHIVES OF SURGERY, 2000, 135 (12) : 1476 - 1476
  • [6] Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma
    Deveci, M. Salih
    Deveci, Guezin
    [J]. GASTRIC CANCER, 2007, 10 (02) : 112 - 116
  • [7] Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma
    M. Salih Deveci
    Güzin Deveci
    [J]. Gastric Cancer, 2007, 10 : 112 - 116
  • [8] p53 tumor suppressor gene protein expression in premalignant and malignant skin lesions of kidney transplant recipients
    Gibson, GE
    OGrady, A
    Kay, EW
    Leader, M
    Murphy, GM
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 36 (06) : 924 - 931
  • [9] Detection of p53 tumor suppressor gene mutation in advanced gastric carcinoma is not independently prognostic
    Fuke, T
    Iinuma, H
    Fukushima, R
    Okinaga, K
    [J]. XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1996, : 343 - 346
  • [10] Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression
    Shin, DM
    Mao, L
    Papadimitrakopoulou, VM
    Clayman, G
    El-Naggar, A
    Shin, HJC
    Lee, JJ
    Lee, JS
    Gillenwater, A
    Myers, J
    Lippman, SM
    Hittelman, WN
    Hong, WK
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (01) : 69 - 73